Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX

Institute of Tropical Medicine, Belgium

Status: Enrolling

Conditions: Uncomplicated Malaria; Severe Malaria; Asyptomatic Plasmodium Infection

Study type: Observational

Funder types: Other

Identifiers

NCT06064591

IMMETASEX 1704/23

G067823N (Other Grant/Funding Number)

Details and patient eligibility

About

Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections.

Full description

Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. At each replicating cycle within erythrocytes, a proportion of asexual parasites converts into non-replicative sexual stages, which are the only forms able to infect mosquitos. The rate at which sexual stages are produced, is known as basal sexual conversion rate. Changes in the host immune and metabolic environment associated with the development of malaria disease, such as depletion of lysophosphatidylcholine in plasma, have been associated with increased sexual conversion rates in vitro. It is hypothesised that immune and metabolite factors that are altered during malaria infection induce sexual conversion in Plasmodium falciparum parasites. In this project, a new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections. The aim is to identify immune factors and metabolites that induce sexual conversion using in-house developed sexual conversion assays, and experimental mosquito infections. Finally, transcriptional mechanisms are explored driving parasite sexual conversion in the host environment during disease using single-cell RNA-sequencing approaches. This research will provide essential knowledge on the factors that affect sexual conversion in the host and potentially inform novel strategies to interrupt transmission.

Enrollment: 430 estimated patients

Sex: All

Ages: 1+ year old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age: ≥ 1 year
• Willing and able to provide written informed consent (or assent for minors with written informed consent by parent(s) and/or guardian(s).

Pilot:

-symptomatic for P. falciparum

-/Travel to P. falciparum endemic area within the last month

WP1:

• Resident in Nanoro district
• non-symptomatic individuals

WP2:

• Positive for P. falciparum infection via Rapid Diagnostic Tests (RDT)
• Age: ≥ 1 and ≤ 12 years
• Patients are included when suspected of the following conditions:

I. Severe malaria by infection with P. falciparum is defined in the presence of P. falciparum asexual parasitemia, and as one or more of the following:

1. Impaired consciousness: A Blantyre coma score < 3 (when patients are ≤ 6 years) or Glasgow coma score < 10 (when patients are ≥ 6 years).
2. Prostration: Generalized weakness so that the person is unable to sit, stand or walk without assistance.
3. Multiple convulsions: More than two episodes within 24 hours.
4. Clinical manifestation of respiratory distress (e.g., rapid, deep and labored breathing).
5. Diagnosis through exclusion: absence of an identified alternative cause.

II. Uncomplicated malaria by infection with P. falciparum is defined as a patient who presents with lethargic profile (e.g. fever) and a positive parasitological test for P. falciparum, but with no features of severe malaria.

Exclusion criteria

• Delayed developmental status or history of chronic illness
• Participation in another study
• Previous malaria treatment or prophylaxis in the last week
• Inability or unwillingness of the parents or guardians to provide informed consent

WP1:

• Symptoms of malaria, as defined by presence of fever (body temperature >37.5 °C or history of fever during the past 48 hours) with a positive RDT (RDT are performed always when there is presence of fever)
• Any plans to leave the study are in the coming 10 days

WP2:

• Severe anemia (will be determined via clinical examination), since blood samples can hardly be withdrawn, co-morbidities.
• A questionnaire will be used during the clinical assessment that addresses following exclusion criteria:

x Antimalarial drug treatment or other medication during the past week x If the patient had a meal within 4 hours before admission x Patients with acute meningitis (as clinically evaluated according to the local guidelines) x Patients with developmental delay or history of chronic illness x Vaccination during the past week

Trial design

430 participants in 7 patient groups

Pilot study Belgium Patients

Description:

Patients (P. falciparum-infected) No intervention 6 ml of venous blood sampled at one time point

Pilot study Belgium Controls

Description:

Control non-infected individuals No intervention 6 ml of venous blood sampled at one time point

Work package 1 Burkina Faso Asymptomatic

Description:

Asymptomatic (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point. 300µl of finger prick blood at four follow-up visits 24, and 48 and 72h and day 10 after the enrollment.

Work package 1 Burkina Faso uncomplicated patients

Description:

uncomplicated patients (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point.

Work package 1 Burkina Faso Controls

Description:

Control non-infected individuals No intervention Venous blood sample (maximum of 8 ml) at 1 time point.

Work package 2 Mozambique Uncomplicated malaria patients

Description:

Uncomplicated malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.

Work package 2 Mozambique Severe malaria patients

Description:

Severe malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.